| 产品名称：英夫利昔（inlfiximab）抗体ELISA试剂盒 | |
| 型 号：TR-Q-INFLIXIv2 | |
| 所属分类：土耳其matriks试剂盒 | |
| 价格：12000 | |
| 包装：96t | |
| 生产地：土耳其 |
| 样本量(µl) | 10 |
|---|---|
| 总时间 (min) | 70 |
| 测试样本 | Serum, plasma |
| 包装规格（T） | 96 |
| 灵敏度 (ng/mL) | 30 |
| 回收率 (%) | 97 |
| 有效期 (年) | 1 |
Infliximab，注册商标为Remicade，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。
英夫利昔单抗（Infliximab，Remicade）是一类相对新型的生物制剂。为高亲和性结合肿瘤坏死因子alpha (TNF-α)的嵌合体单抗，其被广泛应用于治疗自身免疫性疾病。因此，检测英夫利昔单抗、抗英夫利昔抗体血药浓度及水平在治疗和个性化用药上具有重要意义。
Matriks Biotechnology专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内浓度或因用该抗体药产生的抗体的体内浓度。Matriks Biotek®, SHIKARI®和KLONART®为Matriks Biotechnology注册的产品商标。其产品达到ISO 13485 & CE IVD标准。
英夫利昔(Infliximab， Remicade®) ELISA (Specific) 试剂盒
英文名称：SHIKARI® QS-INFLIXI ELISA KIT； 货号：TR-QS-INFLIXlv1； 规格：96T
英文描述：Enzyme immunoassay for the quantitative determination of Infliximab (Remicade®) in serum and plasma and other biological fluids
中文描述：ELISA方法特异性定量测定血清、血浆或其他生物液体中的英夫利昔单抗(Infliximab， Remicade®)的浓度
SHIKARI Q-INFLIXI ELISA KIT使用单克隆抗体高专一性结合血清、血浆或其他生物液中的英夫利昔单抗(Infliximab， Remicade®)，是当前*一款用于定量检测英夫利昔(Infliximab， Remicade®)体内浓度的特异性ELISA试剂盒。
引用文献：
| # |
PEER REVIEWED JOURNAL ARTICLES: |
|
|---|---|---|
| 1 | Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.** | |
| 4 | Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.** | |
| 6 | Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published April 21, 2016. | |
| 7 | Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol. Apr;111(4):529-40, 2016. | |
| 8 | Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.** | |
| 9 | Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155–166 ** | |
| 10 | Bortlik M., et al., Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol. 51, no. 2, 196–202. | |
| 11 | Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.** | |
| 14 | Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol (2015) 50:758–768. | |
| 16 | Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015. | |
| 17 | Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis experiences from a single center. Expert Opin. Biol. Ther. 15:(9) 2015. | |
| 18 | Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to ‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737–743), 2015. | |
| 19 | Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.** | |
| 22 | Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. ** | |
| 23 | Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. ** | |
| 24 | Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology& Hepatology 26:(485-487), 2014. | |
| 27 | Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014. | |
| 29 | Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. ** | |
| 30 | Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. ** | |
| 33 | Bortlik M et al, “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study”, Scandinavian Journal of Gastroenterology. 48: 951–958, 2013 | |
| 34 | Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis 2012. ** | |
| 35 | Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. ** | |
| 36 | Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. ** | |
| 37 | Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249 ** | |
| 38 | Molnar T, et al, “Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease”, Z Gastroenterol 2012; 50 – A53 | |
| 39 | Kato S, et al, “Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient”, Crohn’s & Colitis Foundation of America 2011 | |
| 40 | Adisen E, et al, “Anti-infliximab antibody status and its relation to clinical response in psoriatic patients”: A pilot study, Journal of Dermatology 2010; 37: 708–713. |
Matriks Biotechnology——抗体药的药效及个体化应用专家
抗体药是一类相对新型的生物制剂。检测抗体药及其抗体水平在治疗和个性化用药上具有重要意义。大量的临床和制药公司都在致力于抗体药物的浓度水平和疗效的研究。Matriks生物技术公司专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内含量或因用于产生的针对相应抗体药的抗体的体内含量。Matriks Biotek?, SHIKARI?和KLONART?为Matriks生物技术公司注册的产品商标。其产品达到ISO 13485 & CE IVD标准。
Matriks生产用于检测抗体药在体内的浓度和疗效的试剂盒主要针对如下几种抗体药。
1. Infliximab注册商标为Remicade，由Schering-Plough生产，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。
Infliximab为高亲和性结合肿瘤坏死因子alpha (TNF-α)的嵌合体单抗，其被广泛应用于治疗自身免疫性疾病。Matriks Biotek Shikari Infliximab ELISA使用单克隆抗体高专一性结合血清、血浆和其他生物液中的Infliximab，是当前*的一款用于定量检测Infliximab (Remicade?)体内含量的特异性ELISA试剂盒。
2. Adalimumab注释商标为Humira, 为Abbott Laboratories产品，中文名阿达木单抗、修美乐。
Adalimumab为特异性结合TNF-α的人源性抗体，Adalimumab通过阻止TNF-α与其细胞表面受体相结合，发挥抗炎作用。
Matriks Biotek shikari抗体检测抗Adalimumab抗体，用于检测治疗过程中抗Adalimumab抗体状况，为医师提供时机以减少抗Adalimumab抗体产生（例如添加免疫抑制性药物），以阻止抗体药失效。
3. Etanercept商标为Enbrel和Altebrel，中文名依那西普，恩利.
是一种干扰TNF-α、用于自身免疫性疾病治疗的生物药物。针对Etanercept的特异性单抗用于检测血样中Etanercept量。Matriks Biotek Shikari Q-ETA是市面上用于定量检测Etanercept的ELISA试剂盒。
4. 人肿瘤坏死因子及受体
Matriks Biotek开发的高敏感度、专一性TNF-α检测试剂盒，该试剂盒基于固定在固相面上的针对TNF-alpha的单抗和标记了马辣根过氧化物酶的另一单抗经三明治夹心法检测TNF-α。
5. Bevacizumab商标名为Avastin?，由Genentech/Roche生产，中文名为阿瓦斯汀、贝伐单抗、安维汀、癌思停。
Bevacizumab为血管生成抑制剂，在包括结肠和直肠癌、肺癌、乳腺癌、肾癌、卵巢癌等多种肿瘤中被批准使用。Matriks Biotek Shikari Q-BEVA Enzyme Immunoassay用于检测血清或血浆中游离bevacizumab含量。以便保证其有效的血药浓度。
6. Rituximab商标为Rituxan, Mabthera, Zytux，中文名为利妥昔单抗注射剂、美罗华、利妥昔单抗、利克散、贺普丁、莫須瘤。
Rituximab为针对B细胞表面抗原CD20蛋白的嵌合型单克隆抗体。Rituximab可破坏B细胞，从而用于治疗包括多种白血病、淋巴瘤、移植排斥和自身免疫失调性疾病等多种因B细胞过量、B细胞高反应性和B细胞功能失调引起的疾病。Rituximab的使用可引起机体产生相应抗体。Matriks Biotek Rituximab-ELISA和Rituximab抗体分别用于测定机体内rituximab及其抗体的水平，从而为维持有效rituximab的血药浓度和提供抗抗体措施提供预防性举措。
7. Trastuzumab商标名为Herclon, Herceptin，中文名为赫赛汀、賀癌平、曲妥珠单抗。
Trastuzumab为干扰HER2/neu受体的单克隆抗体，其主要用于乳腺癌的治疗。Trastuzumab的使用可导致机体产生抗Trastuzumab抗体。Matriks Biotek Trastuzumab-ELISA和抗体分别用于检测机体trastuzumab和其抗体的浓度。
Matriks Biotek抗体药个性化用药测试盒产品目录
|
中文名称 |
英文名称 |
货号 |
规格 |
|
Infliximab，商标Remicade，英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克 |
|||
|
英夫利昔单抗（类克）ELISA试剂盒 |
SHIKARI QS-INFLIXI ELISA KIT |
TR-QS-INFLIXIv1 |
96T |
|
英夫利昔单抗（类克）ELISA试剂盒 |
SHIKARI Q-INFLIXI ELISA KIT |
TR-Q-INFLIXIv2 |
96T |
|
抗英夫利昔单抗（类克）抗体ELISA试剂盒 |
SHIKARI Q-ATI ELISA KIT |
TR-ATIv4 |
96T |
|
Adalimumab，商标Humira，阿达木单抗、修美乐 |
|||
|
阿达木单抗（修美乐）ELISA试剂盒 |
SHIKARI Q-ADA ELISA KIT |
TR-ADAv1 |
96T |
|
抗阿达木单抗（修美乐）抗体ELISA试剂盒 |
SHIKARI S-ATA ELISA KIT |
TR-A-ADAv1 |
96T |
|
Etanercept，商标Enbrel、Altebrel，依那西普、恩利 |
|||
|
依那西普（恩利）ELISA试剂盒 |
SHIKARI Q-ETA ELISA KIT |
TR-ETAv1 |
96T |
|
抗依那西普（恩利）抗体ELISA试剂盒 |
SHIKARI S-ATE ELISA KIT |
TR-AETAv2 |
96T |
|
人肿瘤坏死因子及受体 |
|||
|
TNF-αELISA试剂盒 |
SHIKARI Q-TNF ELISA KIT |
TR-TNFv1 |
96T |
|
TNF-RII（p75/80 kDa）ELISA试剂盒 |
SHIKARI Q-sTNF-RII ELISA KIT |
TR-sTNF-RIIv1 |
96T |
|
Bevacizumab，商标Avastin，阿瓦斯汀、贝伐单抗、安维汀、癌思停 |
|||
|
贝伐单抗（安维汀）ELISA试剂盒 |
SHIKARI Q-BEVA ELISA KIT |
TR-BEVAv1 |
96T |
|
抗贝伐单抗（安维汀）抗体ELISA试剂盒 |
SHIKARI S-ATB ELISA KIT |
TR-ABEVAv1 |
96T |
|
Rituximab，商标Rituxan、Mabthera，利妥昔单抗、美罗华、利克散、贺普丁、莫須瘤 |
|||
|
利妥昔单抗（美罗华）ELISA试剂盒 |
SHIKARI Q-RITUX ELISA KIT |
TR-RTXv1 |
96T |
|
抗利妥昔单抗（美罗华）抗体ELISA试剂盒 |
SHIKARI S-ATR ELISA KIT |
TR-ARTXv1 |
96T |
|
Trastuzumab，商标Herclon,、Herceptin，曲妥珠单抗、赫赛汀、賀癌平 |
|||
|
曲妥珠单抗（赫赛汀）ELISA试剂盒 |
SHIKARI Q-TRAS ELISA KIT |
TR-TRASv1 |
96T |
|
抗曲妥珠单抗（赫赛汀）抗体ELISA试剂盒 |
SHIKARI S-ATT ELISA KIT |
TR-ATRASv1 |
96T |
上海金畔生物科技有限公司